Eden Bioscience Corporation (NASDAQ: EDEN) today announced that it received a Nasdaq Staff Determination Letter on April 3, 2006 stating that the Company’s common stock had not regained compliance with the $1 minimum bid price continued listing requirement set forth in Marketplace Rule 4310(c)(4) during the 180-day extension period provided the Company on October 10, 2005. Consequently, the Company’s common stock is subject to delisting from The Nasdaq Capital Market at the opening of business on April 12, 2006. The Company has requested a hearing before a Nasdaq Listing Qualifications Panel to review the Staff Determination, which will stay the delisting action pending the issuance of a final decision by the Panel. There can be no assurance the Panel will grant the Company’s request for continued listing.
